Articles related to DRUG SAFETY & INTERACTIONS

Laboratory analysis reveals montelukast demonstrates “significant binding” to multiple brain receptors, suggesting more extensive neurological activity than previously understood.

23 million Americans take levothyroxine daily, making it one of the nation’s most prescribed medications, with new evidence suggesting potential risks to bone health even at standard therapeutic levels.

Adverse events from compounded semaglutide have led to hundreds of hospitalizations, highlighting critical safety concerns for healthcare providers managing patients seeking weight loss solutions.

The FDA-designated Class II recall affects specific duloxetine lots where exposure may lead to “temporary or medically reversible health consequences or where the probability of serious adverse health consequences is remote.”

Analysis of 285,680 patients shows a 1.03-1.38% reduction in cumulative mortality with rosuvastatin compared to atorvastatin, alongside varying risks for cardiovascular events, liver outcomes, and diabetes.

Risk of dementia with these medications increases proportionally with higher doses and extended duration of use, emphasizing the importance of minimal effective dosing strategies.